The Effect of Indomethacin in Monosymptomatic Enuresis Nocturnal
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Monosymptomatic nocturnal enuresis, defined as the involuntary loss of urine during the night
at an age where voluntary bladder control should have been attained and on the background of
normal urinary tract function, is a rather common disease of childhood with an estimated
prevalence of 5-10% at tha age of 7 and a spontaneous remission rate of 15% per year.
The present study consists of two phases; an in-patient phase and an ambulatory phase.
In the in-patient phase we will examine the regulation of sodium and the circadian rhythm of
the hormones that affect this regulation in children with enuresis nocturnal and healthy
children, as well as the impact of indomethacin on renal water and electrolyte excretion.
In the ambulatory phase we will examine the efficacy and safety of a treatment modality
consisting of a combination of dDAVP and indomethacin in patients with severe enuresis where
dDAVP as monotherapy is inadequate.
A significant number of children with enuresis and nocturnal polyuria do not respond to
treatment with dDAVP. If a combination treatment with dDAVP and indomethacin proves superior
to dDAVP alone the regimen could readily be used in those difficult to cure cases of
enuresis.